Patent SG-11201804263P-A (SG)
Title: Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
Inventor: GARDAI SHYRA
IPC: C07K16/32
Filed: 2016-12-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ristspi id (43) International Publication Date .... .....r ,„„0 8 June 2017 (08.06.2017) W I P0 1 PCT ID Hit (10) 11111111 WO Ill International 1111111111 IIIII II 2017/096274 III IIIIIIIIIIIIIII Publication IIIIIIIIIIIIII Al Number RIO IIII IIIIIIII (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/7024 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/7042 (2006.01) C07K 16/28 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/70 (2006.01) C07K 16/32 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/02 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/064783 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 2 December 2016 (02.12.2016) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/263,228 4 December 2015 (04.12.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/308,583 15 March 2016 (15.03.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/321,857 13 April 2016 (13.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: SEATTLE GENETICS, INC. [US/US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 21823 30th Drive SE, Bothell, Washington 98021 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: GARDAI, Shyra; 21823 30th Drive SE, GW, KM, ML, MR, NE, SN, TD, TG). Bothell, Washington 98021 (US). LAW, Che-Leung; Declarations under Rule 4.17: 21823 30th Drive SE, Bothell, Washington 98021 (US). be — as to applicant's entitlement to apply for and granted a SENTER, Peter; 21823 30th Drive SE, Bothell, Washing- patent (Rule 4.170) ton 98021 (US). OKELEY, Nicole; 21823 30th Drive SE, Bothell, Washington 98021 (US). FIELD, Jessica; 21823 — as to the applicant's entitlement to claim the priority of the 30th Drive SE, Bothell, Washington 98021 (US). earlier application (Rule 4.17(iii)) (74) Agents: LIN, Min al.; Seattle Genetics, Inc., 21823 30th Published: et Drive SE, Bothell, Washington 98021 (US). — with international search report (Art 21(3)) Title: CANCER TREATMENT USING 2-DEOXY-2-FLUORO-L-FUCOSE IN COMBINATION WITH A CHECKPOINT (54) INHIBITOR Figure 11 100 AP- Untreated -M-2FF To 80- -A- Anti-PD1 91 60- m -0- 2FF + Anti-PD1 Cl) . 6' 1-1 a) 40 - .4t 2 a) il• 0 - 20- 11\" - - el 0. . . . C) 0 01 0 IN 1-1 O (57) : The present invention is an effective amount of 2-deoxy-2-fluoro-L-fucose 0 with a checkpoint inhibitor. 20 40 60 80 100 Days post tumor implant directed to methods for treating cancer comprising administering to a subject in need thereof or a prodrug thereof, or a pharmaceutically acceptable salt thereof, in combination